Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SUMANA GANGI

Allopathic & Osteopathic Physicians Internal Medicine Endocrinology, Diabetes & Metabolism

NPI
1487679213
CMS profile
158261
Location
MESQUITE, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$79,132.26

205 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

By paying entity

PY2023 · entire year · sorted by reported total

Page 3 of 5; records 101–150 of 205 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SUMANA GANGI

NPI 1487679213 · CMS profile ID 158261

Allopathic & Osteopathic Physicians / Internal Medicine / Endocrinology, Diabetes & Metabolism

MESQUITE, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 5; records 101–150 of 205 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1487679213?year=2023&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SUMANA GANGI, NPI 1487679213, CMS profile ID 158261. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 5; records 101–150 of 205 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1487679213?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). SUMANA GANGI, NPI 1487679213, CMS profile ID 158261. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 5; records 101–150 of 205 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1487679213?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
SUMANA GANGI, NPI 1487679213, CMS profile ID 158261, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 5; records 101–150 of 205 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1487679213?year=2023&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

205 matching records · $79,132.26 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 205 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 205.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Lilly USA, LLC $900.0005/26/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032145809 CMS
Lilly USA, LLC $55.6805/26/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032359859 CMS
IBSA Pharma Inc. $14.7205/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999711289 CMS
Novo Nordisk Inc $750.0005/25/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000211217 CMS
Novo Nordisk Inc $750.0005/25/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000211225 CMS
Lilly USA, LLC $900.0005/24/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032222751 CMS
Novo Nordisk Inc $750.0005/24/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000211213 CMS
Lilly USA, LLC $31.4405/22/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032145805 CMS
MannKind Corporation $17.1205/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056264507 CMS
Insulet Corporation $17.2805/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016950971 CMS
Lilly USA, LLC $900.0005/18/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032222739 CMS
Lilly USA, LLC $1,125.0005/17/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032193577 CMS
Lilly USA, LLC $43.2305/17/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032222745 CMS
Lilly USA, LLC $1,800.0005/17/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032405203 CMS
Lilly USA, LLC $900.0005/16/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032405223 CMS
Lilly USA, LLC $900.0005/15/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032276867 CMS
Lilly USA, LLC $1,800.0005/11/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032193585 CMS
Lilly USA, LLC $20.9605/11/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032276873 CMS
Lilly USA, LLC $675.0005/11/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032405213 CMS
Lilly USA, LLC $108.8305/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032405241 CMS
Novo Nordisk Inc $4.5605/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000211156 CMS
Novo Nordisk Inc $12.6505/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000211163 CMS
Lilly USA, LLC $1,800.0005/08/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032222733 CMS
Lilly USA, LLC $900.0005/08/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032276857 CMS
Lilly USA, LLC $675.0005/08/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032359831 CMS
Lilly USA, LLC $1,800.0005/04/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032276863 CMS
Lilly USA, LLC $675.0005/04/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032359841 CMS
Amarin Pharma Inc. $16.1105/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000901551 CMS
Lilly USA, LLC $17.3005/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032276853 CMS
Lilly USA, LLC $17.9805/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032222695 CMS
Lilly USA, LLC $49.7804/24/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032193571 CMS
Lilly USA, LLC $675.0004/21/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032222721 CMS
Lilly USA, LLC $1,800.0004/21/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032359825 CMS
Lilly USA, LLC $35.3704/21/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032405195 CMS
Lilly USA, LLC $17.2004/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032359849 CMS
Lilly USA, LLC $16.6504/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032315327 CMS
Lilly USA, LLC $0.9804/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032315335 CMS
Novo Nordisk Inc $1,993.7504/18/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000211357 CMS
Lilly USA, LLC $675.0004/14/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032222715 CMS
Lilly USA, LLC $1,800.0004/14/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032315319 CMS
Lilly USA, LLC $675.0004/13/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032222711 CMS
Lilly USA, LLC $1,800.0004/13/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032359817 CMS
Lilly USA, LLC $19.1904/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032222727 CMS
Lilly USA, LLC $20.5404/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032276837 CMS
Lilly USA, LLC $900.0004/12/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032315313 CMS
Lilly USA, LLC $18.1904/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032193565 CMS
PFIZER INC. $24.6204/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049157517 CMS
LIFESCAN, INC. $16.7704/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 975249837 CMS
AstraZeneca Pharmaceuticals LP $16.4904/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011266059 CMS
Amarin Pharma Inc. $19.5103/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000912017 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $247,757.04 421
PY2020 $128,358.36 289
PY2021 $97,804.25 234
PY2022 $137,618.64 267
PY2023 $79,132.26 205
PY2024 $44,068.29 171
PY2025 $52,382.04 199

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $7,981.00 1
PY2025 Principal investigator $2,974,665.83 53
PY2024 Recipient $88,352.26 17
PY2024 Principal investigator $2,670,003.99 46
PY2023 Recipient $131,216.93 6
PY2023 Principal investigator $2,681,956.08 31
PY2022 Recipient $87,596.00 7
PY2022 Principal investigator $1,486,475.28 29
PY2021 Recipient $15,865.15 4
PY2021 Principal investigator $1,366,963.78 30
PY2020 Recipient $892.37 3
PY2020 Principal investigator $795,414.57 29
PY2019 Recipient $18,765.41 5
PY2019 Principal investigator $395,501.86 32

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

54 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $5,692.00 12/31/2025 Non-covered Recipient Entity
SOUTHERN ENDOCRINOLOGY ASSOCIATES
A Phase 2/3 multicenter, double blinded, randomized, dose-conversion, active control study examining the efficacy and safety of Armour Thyroid compared to synthetic T4 for the treatment of adults with primary hypothyroidism No dispute reported 06/30/2026 1202533449
Principal investigator 1 Eli Lilly and Company $915.38 12/17/2025 Non-covered Recipient Entity
SOUTHERN ENDOCRINOLOGY ASSOCIATES PA
A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE PHARMACOLOGIC AGENTS IN ADULT PARTICIPANTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE WHO ARE AT INCREASED RISK OF DEVELOPING MAJOR ADVERSE LIVER OUTCOMES No dispute reported 06/30/2026 1187888108
Principal investigator 1 Eli Lilly and Company $1,395.66 12/17/2025 Non-covered Recipient Entity
SOUTHERN ENDOCRINOLOGY ASSOCIATES PA
A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE PHARMACOLOGIC AGENTS IN ADULT PARTICIPANTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE WHO ARE AT INCREASED RISK OF DEVELOPING MAJOR ADVERSE LIVER OUTCOMES No dispute reported 06/30/2026 1187890910
Principal investigator 1 Eli Lilly and Company $10,750.00 11/06/2025 Non-covered Recipient Entity
SOUTHERN ENDOCRINOLOGY ASSOCIATES PA
Not supplied No dispute reported 06/30/2026 1187891330
Principal investigator 1 ABBVIE INC. $29,457.30 11/05/2025 Non-covered Recipient Entity
SOUTHERN ENDOCRINOLOGY ASSOCIATES
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202522581
Principal investigator 1 ABBVIE INC. $19,994.20 10/09/2025 Non-covered Recipient Entity
SOUTHERN ENDOCRINOLOGY ASSOCIATES
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202513877
Principal investigator 1 Ionis Pharmaceuticals, Inc. $1,275.00 10/08/2025 Non-covered Recipient Entity
SOUTHERN ENDOCRINOLOGY ASSOCIATES PA
IS354CS9 No dispute reported 06/30/2026 1246788440
Principal investigator 1 Ionis Pharmaceuticals, Inc. $4,080.00 10/08/2025 Non-covered Recipient Entity
SOUTHERN ENDOCRINOLOGY ASSOCIATES PA
IS354CS9 No dispute reported 06/30/2026 1246788444
Principal investigator 1 Ionis Pharmaceuticals, Inc. $26,042.00 10/08/2025 Non-covered Recipient Entity
SOUTHERN ENDOCRINOLOGY ASSOCIATES PA
IS354CS9 No dispute reported 06/30/2026 1246788447
Principal investigator 1 ABBVIE INC. $29,859.70 09/04/2025 Non-covered Recipient Entity
SOUTHERN ENDOCRINOLOGY ASSOCIATES
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202509674
Principal investigator 1 Amgen Inc. $3,814.53 08/26/2025 Non-covered Recipient Entity
SOUTHERN ENDOCRINOLOGY ASSOCIATES PA
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing Olpasiran Use to Prevent First Major Cardiovascular Events in Participants With Elevated Lipoprotein(a) No dispute reported 06/30/2026 1246648443
Principal investigator 1 ABBVIE INC. $23,753.20 08/06/2025 Non-covered Recipient Entity
SOUTHERN ENDOCRINOLOGY ASSOCIATES
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202503107
Principal investigator 1 Ionis Pharmaceuticals, Inc. $4,156.20 08/06/2025 Non-covered Recipient Entity
SOUTHERN ENDOCRINOLOGY ASSOCIATES PA
IS354CS15 No dispute reported 06/30/2026 1246786155
Principal investigator 1 Amgen Inc. $624.00 08/01/2025 Non-covered Recipient Entity
SOUTHERN ENDOCRINOLOGY
A Study to Evaluate the Efficacy, Safety & Tolerability of Maridebart Cafraglutide in Adults With T2DM No dispute reported 06/30/2026 1246648462
Principal investigator 1 Amgen Inc. $24,457.00 08/01/2025 Non-covered Recipient Entity
SUMANA GANGI
A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Impact of Evolocumab on Major Cardiovascular Events in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke No dispute reported 06/30/2026 1246648874
Principal investigator 1 ABBVIE INC. $19,437.50 07/02/2025 Non-covered Recipient Entity
SOUTHERN ENDOCRINOLOGY ASSOCIATES
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202494683
Principal investigator 1 Eli Lilly and Company $331,578.94 06/16/2025 Non-covered Recipient Entity
SOUTHERN ENDOCRINOLOGY ASSOCIATES PA
A PHASE 3B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE RETATRUTIDE TREATMENT IN THE MAINTENANCE OF WEIGHT REDUCTION IN INDIVIDUALS WITH OBESITY No dispute reported 06/30/2026 1187889844
Principal investigator 1 Amgen Inc. $16,749.94 06/10/2025 Non-covered Recipient Entity
SOUTHERN ENDOCRINOLOGY ASSOCIATES PA
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity No dispute reported 06/30/2026 1246648456
Principal investigator 1 Eli Lilly and Company $173,803.00 06/10/2025 Non-covered Recipient Entity
SOUTHERN ENDOCRINOLOGY ASSOCIATES PA
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY EVALUATING THE EFFICACY AND LONG-TERM SAFETY OF TIRZEPATIDE ONCE WEEKLY COMPARED TO PLACEBO IN ADULTS WITH TYPE 1 DIABETES AND OBESITY OR OVERWEIGHT (SURPASS-T1D-2) No dispute reported 06/30/2026 1187891366
Principal investigator 1 ABBVIE INC. $58,683.80 06/03/2025 Non-covered Recipient Entity
SOUTHERN ENDOCRINOLOGY ASSOCIATES
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202489863
Principal investigator 1 Eli Lilly and Company $73,513.00 05/27/2025 Non-covered Recipient Entity
SOUTHERN ENDOCRINOLOGY ASSOCIATES PA
A PARALLEL-GROUP TREATMENT, PHASE 2, DOUBLE-BLIND STUDY OF ONCE-WEEKLY SUBCUTANEOUS LY3457263 COMPARED TO PLACEBO IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS ON A STABLE DOSE OF TIRZEPATIDE OR SEMAGLUTIDE WHO FAILED TO ACHIEVE HBA1C GOAL No dispute reported 06/30/2026 1187888106
Principal investigator 1 ABBVIE INC. $16,608.80 05/07/2025 Non-covered Recipient Entity
SOUTHERN ENDOCRINOLOGY ASSOCIATES
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202483987
Recipient Amgen Inc. $7,981.00 04/24/2025 Covered Recipient Physician A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Impact of Evolocumab on Major Cardiovascular Events in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke No dispute reported 06/30/2026 1246637014
Principal investigator 1 ABBVIE INC. $4,176.90 04/03/2025 Non-covered Recipient Entity
SOUTHERN ENDOCRINOLOGY ASSOCIATES
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202468775
Principal investigator 1 Eli Lilly and Company $270.51 04/03/2025 Non-covered Recipient Entity
SOUTHERN ENDOCRINOLOGY ASSOCIATES PA
A STUDY OF ORFORGLIPRON FOR THE MAINTENANCE OF BODY WEIGHT REDUCTION IN PARTICIPANTS WHO HAVE OBESITY OR OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES (ATTAIN-MAINTAIN) No dispute reported 06/30/2026 1187891292
Principal investigator 1 Eli Lilly and Company $116.44 03/13/2025 Non-covered Recipient Entity
UNIVERSITY OF TEXAS HEALTH
A STUDY OF ORFORGLIPRON FOR THE MAINTENANCE OF BODY WEIGHT REDUCTION IN PARTICIPANTS WHO HAVE OBESITY OR OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES (ATTAIN-MAINTAIN) No dispute reported 06/30/2026 1187891992
Principal investigator 1 ABBVIE INC. $15,069.60 03/07/2025 Non-covered Recipient Entity
SOUTHERN ENDOCRINOLOGY ASSOCIATES
M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202459329
Principal investigator 1 Merck Sharp & Dohme LLC $2,500.00 02/24/2025 Non-covered Recipient Entity
Southern Endocrinology and Associates PA
A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled Clinical Study to Evaluate the Safety and Efficacy of Ertugliflozin MK-8835,PF-04971729 in Pediatric Participants ages 10 to 17 years, inclusive with Type 2 Diabetes Mellitus No dispute reported 06/30/2026 1232933078
Principal investigator 1 ABBVIE INC. $22,991.80 02/06/2025 Non-covered Recipient Entity
SOUTHERN ENDOCRINOLOGY ASSOCIATES
M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202449663
Principal investigator 1 Eli Lilly and Company $216.36 01/31/2025 Non-covered Recipient Entity
SOUTHERN ENDOCRINOLOGY ASSOCIATES PA
A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) No dispute reported 06/30/2026 1187891364
Principal investigator 1 Amgen Inc. $143,431.36 01/27/2025 Non-covered Recipient Entity
SOUTHERN ENDOCRINOLOGY ASSOCIATES PA
A Study to Evaluate the Efficacy, Safety & Tolerability of Maridebart Cafraglutide in Adults With T2DM No dispute reported 06/30/2026 1246648459
Principal investigator 1 Eli Lilly and Company $2,785.88 01/27/2025 Non-covered Recipient Entity
SOUTHERN ENDOCRINOLOGY ASSOCIATES PA
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) No dispute reported 06/30/2026 1187888908
Principal investigator 1 Eli Lilly and Company $576.02 01/27/2025 Non-covered Recipient Entity
SOUTHERN ENDOCRINOLOGY ASSOCIATES PA
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY No dispute reported 06/30/2026 1187889678
Principal investigator 1 Eli Lilly and Company $1,404.21 01/27/2025 Non-covered Recipient Entity
SOUTHERN ENDOCRINOLOGY ASSOCIATES PA
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3437943 ONCE WEEKLY COMPARED TO PLACEBO IN PARTICIPANTS WITH SEVERE OBESITY AND ESTABLISHED CARDIOVASCULAR DISEASE No dispute reported 06/30/2026 1187889840
Principal investigator 1 Eli Lilly and Company $2,353.22 01/27/2025 Non-covered Recipient Entity
SOUTHERN ENDOCRINOLOGY ASSOCIATES PA
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF INVESTIGATIONAL TIRZEPATIDE DOSES IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY No dispute reported 06/30/2026 1187891290
Principal investigator 1 Eli Lilly and Company $956.44 01/27/2025 Non-covered Recipient Entity
SOUTHERN ENDOCRINOLOGY ASSOCIATES PA
A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH ORAL SEMAGLUTIDE IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN (ACHIEVE-3) No dispute reported 06/30/2026 1187891328
Principal investigator 1 Eli Lilly and Company $72,070.00 01/21/2025 Non-covered Recipient Entity
SOUTHERN ENDOCRINOLOGY ASSOCIATES PA
THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SURPASS CVOT) No dispute reported 06/30/2026 1187889834
Principal investigator 1 Eli Lilly and Company $116,844.00 01/21/2025 Non-covered Recipient Entity
SOUTHERN ENDOCRINOLOGY ASSOCIATES PA
A STUDY OF ORFORGLIPRON FOR THE MAINTENANCE OF BODY WEIGHT REDUCTION IN PARTICIPANTS WHO HAVE OBESITY OR OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES (ATTAIN-MAINTAIN) No dispute reported 06/30/2026 1187889836
Principal investigator 1 Eli Lilly and Company $553.49 01/21/2025 Non-covered Recipient Entity
SOUTHERN ENDOCRINOLOGY ASSOCIATES PA
A STUDY OF LY3298176 (TIRZEPATIDE) FOR THE MAINTENANCE OF BODY WEIGHT REDUCTION IN PARTICIPANTS WHO HAVE OBESITY OR OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES No dispute reported 06/30/2026 1187889838
Principal investigator 1 Eli Lilly and Company $17,113.30 01/21/2025 Non-covered Recipient Entity
SOUTHERN ENDOCRINOLOGY ASSOCIATES PA
A PHASE 3, RANDOMIZED, MULTICENTER, DOUBLE-BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RETATRUTIDE ONCE WEEKLY COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES, MODERATE OR SEVERE RENAL IMPAIRMENT WITH INADEQUATE GLYCEMIC CONTROL ON BASAL INSULIN WITH OR WITHOUT METFORMIN AND/OR SGLT2 INHIBITOR No dispute reported 06/30/2026 1187891284
Principal investigator 1 Eli Lilly and Company $2,911.94 01/21/2025 Non-covered Recipient Entity
SOUTHERN ENDOCRINOLOGY ASSOCIATES PA
THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SURPASS CVOT) No dispute reported 06/30/2026 1187891326
Principal investigator 1 Eli Lilly and Company $40,445.00 01/21/2025 Non-covered Recipient Entity
SOUTHERN ENDOCRINOLOGY ASSOCIATES PA
A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH ORAL SEMAGLUTIDE IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN (ACHIEVE-3) No dispute reported 06/30/2026 1187891358
Principal investigator 1 Amgen Inc. $385,507.87 01/13/2025 Non-covered Recipient Entity
SOUTHERN ENDOCRINOLOGY ASSOCIATES PA
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight No dispute reported 06/30/2026 1246648452
Principal investigator 1 Eli Lilly and Company $157,447.00 01/07/2025 Non-covered Recipient Entity
SOUTHERN ENDOCRINOLOGY ASSOCIATES PA
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3437943 ONCE WEEKLY COMPARED TO PLACEBO IN PARTICIPANTS WITH SEVERE OBESITY AND ESTABLISHED CARDIOVASCULAR DISEASE No dispute reported 06/30/2026 1187888102
Principal investigator 1 Eli Lilly and Company $120,138.00 01/07/2025 Non-covered Recipient Entity
SOUTHERN ENDOCRINOLOGY ASSOCIATES PA
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE No dispute reported 06/30/2026 1187888104
Principal investigator 1 Eli Lilly and Company $94,695.00 01/07/2025 Non-covered Recipient Entity
SOUTHERN ENDOCRINOLOGY ASSOCIATES PA
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY No dispute reported 06/30/2026 1187888904
Principal investigator 1 Eli Lilly and Company $110,071.00 01/07/2025 Non-covered Recipient Entity
SOUTHERN ENDOCRINOLOGY ASSOCIATES PA
A PHASE 3, RANDOMIZED, MULTICENTER, DOUBLE-BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RETATRUTIDE ONCE WEEKLY COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES, MODERATE OR SEVERE RENAL IMPAIRMENT WITH INADEQUATE GLYCEMIC CONTROL ON BASAL INSULIN WITH OR WITHOUT METFORMIN AND/OR SGLT2 INHIBITOR No dispute reported 06/30/2026 1187888906
Principal investigator 1 Eli Lilly and Company $67,558.00 01/07/2025 Non-covered Recipient Entity
SOUTHERN ENDOCRINOLOGY ASSOCIATES PA
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF INVESTIGATIONAL TIRZEPATIDE DOSES IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY No dispute reported 06/30/2026 1187889676
Principal investigator 1 Eli Lilly and Company $245,967.00 01/07/2025 Non-covered Recipient Entity
SOUTHERN ENDOCRINOLOGY ASSOCIATES PA
A STUDY OF LY3298176 (TIRZEPATIDE) FOR THE MAINTENANCE OF BODY WEIGHT REDUCTION IN PARTICIPANTS WHO HAVE OBESITY OR OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES No dispute reported 06/30/2026 1187891286
Principal investigator 1 Eli Lilly and Company $182,014.00 01/07/2025 Non-covered Recipient Entity
SOUTHERN ENDOCRINOLOGY ASSOCIATES PA
A PHASE 3, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RETATRUTIDE ONCE WEEKLY COMPARED WITH SEMAGLUTIDE ONCE WEEKLY IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN WITH OR WITHOUT SGLT2 INHIBITOR (TRANSCEND-T2D-2) No dispute reported 06/30/2026 1187891288
Principal investigator 1 Eli Lilly and Company $76,144.00 01/07/2025 Non-covered Recipient Entity
SOUTHERN ENDOCRINOLOGY ASSOCIATES PA
A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) No dispute reported 06/30/2026 1187891360
Principal investigator 1 Eli Lilly and Company $171,143.00 01/07/2025 Non-covered Recipient Entity
SOUTHERN ENDOCRINOLOGY ASSOCIATES PA
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) No dispute reported 06/30/2026 1187891362
Principal investigator 1 Eli Lilly and Company $2,959.34 01/06/2025 Non-covered Recipient Entity
SOUTHERN ENDOCRINOLOGY ASSOCIATES PA
A PHASE 3, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RETATRUTIDE ONCE WEEKLY COMPARED WITH SEMAGLUTIDE ONCE WEEKLY IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN WITH OR WITHOUT SGLT2 INHIBITOR (TRANSCEND-T2D-2) No dispute reported 06/30/2026 1187888902
Principal investigator 1 Amgen Inc. $37,594.00 01/02/2025 Non-covered Recipient Entity
SOUTHERN ENDOCRINOLOGY ASSOCIATES PA
A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Impact of Evolocumab on Major Cardiovascular Events in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke No dispute reported 06/30/2026 1246648448